Suppr超能文献

经活检证实为IgA肾病患者首次及二次肾移植的长期临床结局

Long-term Clinical Outcomes of First and Second Kidney Transplantation in Patients With Biopsy-Proven IgA Nephropathy.

作者信息

Kim Y, Yeo S M, Kang S S, Park W Y, Jin K, Park S B, Park U J, Kim H T, Han S

机构信息

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea.

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; Keimyung University Kidney Institute, Daegu, Republic of Korea.

出版信息

Transplant Proc. 2017 Jun;49(5):992-996. doi: 10.1016/j.transproceed.2017.03.063.

Abstract

INTRODUCTION

The recurrence of IgA nephropathy (IgAN) after kidney transplantation (KT) has an effect on graft survival, but there are few reports about long-term clinical outcomes of KT with recurrent IgAN. This study shows the long-term clinical outcomes of KT in patients with IgAN.

METHODS

All recipients who had biopsy-proven IgAN were followed from February 1990 to February 2016. We analyzed overall graft and patient survival rates, incidence of recurrent IgAN, factors affecting graft survival, and IgAN recurrence.

RESULTS

There were 88 patients with first KT. The mean follow-up duration was 82.5 months. Twenty patients went through graft loss and 1 patient died due to sepsis. IgAN recurred in 15 patients, and 11 patients experienced graft failure. Among the patients who had failed graft after first KT, 7 patients underwent retransplantation. The graft survival period, presence of rejection, and proteinuria were the relevant risk factors for recurrence of IgAN. In the first KT patients, presence of rejection and 1-year serum creatinine were the significant risk factors for graft loss. But recurrence of IgAN was not a relevant risk factor. Overall graft survival rates at 5 and 10 years were 93.8% and 73.1% in the first transplantation group and 100% and 100% in the retransplantation group, respectively.

CONCLUSION

Although IgAN recurrence was a significant risk factor for graft failure, the patient who underwent retransplantation showed favorable results. Retransplantation should be considered in patients who lost their first graft after recurrence of IgAN.

摘要

引言

肾移植(KT)后IgA肾病(IgAN)复发会影响移植肾存活,但关于IgAN复发的肾移植长期临床结局的报道较少。本研究展示了IgAN患者肾移植的长期临床结局。

方法

对所有经活检证实为IgAN的受者进行随访,时间从1990年2月至2016年2月。我们分析了总体移植肾和患者生存率、IgAN复发率、影响移植肾存活的因素以及IgAN复发情况。

结果

88例患者接受了首次肾移植。平均随访时间为82.5个月。20例患者移植肾失功,1例患者因败血症死亡。15例患者IgAN复发,11例患者移植肾失败。在首次肾移植后移植肾失功的患者中,7例患者接受了再次移植。移植肾存活期、排斥反应的存在以及蛋白尿是IgAN复发的相关危险因素。在首次肾移植患者中,排斥反应的存在和1年时的血清肌酐是移植肾失功的显著危险因素。但IgAN复发不是相关危险因素。首次移植组5年和10年的总体移植肾生存率分别为93.8%和73.1%,再次移植组分别为100%和100%。

结论

尽管IgAN复发是移植肾失败的重要危险因素,但接受再次移植的患者结果良好。对于IgAN复发后首次移植肾失功的患者应考虑再次移植。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验